cerebral blood flow; circulation; adrenergic THE MAINTENANCE OF ADEQUATE cerebral blood flow (CBF) is achieved through a variety of physiological processes that buffer the cerebral circulation against changes in the physical and chemical environment (33) . One such process is termed CO 2 reactivity, which refers to the vasoconstriction and vasodilatation of cerebral vessels in response to decreases and increases in the partial pressure of arterial CO 2 (Pa CO 2 ; Ref. 1) . Elevations in CBF with vasodilatation facilitates CO 2 washout from brain tissue during hypercapnia, whereas reductions in CBF with vasoconstriction during hypocapnia attenuate reductions in brain tissue CO 2 . Thus CO 2 reactivity plays an important role in CBF and central pH control.
The precise mechanisms underpinning this vascular response are poorly understood. One area of uncertainty is the extent Pa CO 2 -evoked alterations in the cerebral vascular resistance are mediated through changes in cerebral sympathetic activity (21, 25, 28, 35, 41) . This uncertainty has arisen partly because of interstudy differences in participant populations and experimental methods. For example, clinical studies (28, 41) have generally failed to demonstrate any sympathetic influence on CO 2 reactivity, whereas studies (21, 25, 35, 48) conducted on healthy subjects have produced mixed results. However, comparisons between healthy and diseased populations are liable to confounding because CO 2 reactivity is impaired in many diseases affecting the circulatory system (28, 41) , including hypertension and stroke (36) . Differences in the specificity of methods to modulate sympathetic activity may also contribute to the mixed results in healthy participants. The elimination of sympathetic activity through ganglionic blockade (trimethaphan), for example, has been shown to augment (21) or reduce (35) CO 2 reactivity. It should be noted that trimethaphan also affects cholinergic and histaminergic transmission (12) ; thus treatment effects cannot be ascribed purely to the elimination of sympathetic activity. Studies employing lower body negative pressure as a means of stimulating the sympathetic system have reported reductions (48) or no change (25) in CO 2 reactivity. These studies are limited by the fact that direct cerebral sympathetic neural recordings have failed to confirm the assumption that cerebral sympathetic outflow increases with baroreflex unloading (5, 6) . Finally, most investigations have not included control trials to account for potential confounding due to time of day changes in CO 2 reactivity (2).
Given the aforementioned limitations and considering that CO 2 reactivity has become widely recognized as a surrogate of cerebrovascular reserve (26) , clarification of whether sympathetic activity contributes to CO 2 reactivity is clearly required.
Therefore, the aim of this study was to directly assess the contribution of the sympathetic nervous system to CO 2 reactivity using a selective ␣ 1 -adrenergic blocking agent (prazosin). Since sympathetic excitation evokes vasoconstriction in most vascular beds, and the cerebrovasculature is known to receive sympathetic innervation, we hypothesized that in healthy individuals ␣ 1 -adrenergic blockade would attenuate CO 2 reactivity to hypocapnia (vasoconstriction) but not hypercapnia (vasodilatation).
METHODS

Ethical approval.
Procedures were approved by the New Zealand Central Regional Ethics Committee and conformed to the standards set by the Declaration of Helsinki.
Participants. Eighteen healthy participants with a mean age of 23 yr (range 21-26) and a mean body mass index of 22.8 Ϯ 1.7 kg/m were randomized to placebo (n ϭ 9, 6 female) and active treatment groups (n ϭ 9, 5 female). All participants were screened for respiratory, cardiovascular, and cerebrovascular disease and gave informed written consent. Participants were nonsmokers and were not taking any respiratory or cardiovascular medications. Our required sample size was determined a priori based on previous studies showing a 17-44% change in CO 2 reactivity following sympathetic blockade (21, 35) . Pilot trials indicated that the average baseline CO2 reactivity were ϳ2.54 cm·s Ϫ1 ·mmHg Ϫ1 . Therefore, it was estimated that nine participants would provide Ͼ80% power to detect a minimal change of 0.43 cm·s Ϫ1 ·mmHg Ϫ1 (i.e., 17%) in CO2 reactivity, conservatively assuming a standard deviation of differences of 0.3 and a two-tailed significance level of 0.05.
Measurements. CBF velocity was measured in the M1 segment of the left or right middle cerebral artery (MCA) using 2-MHz pulsed wave transcranial Doppler ultrasound (ST3 Digital Transcranial Doppler System; Spencer Technologies, Seattle, WA). Continuous blood pressure was measured via finger photoelectric plethysmography (Finometer; Finapres Medical Systems, Amsterdam, The Netherlands). Heart rate (HR) was recorded from a three-lead electrocardiogram (ADInstruments, Colorado Springs, CO), and partial pressure of end-tidal CO 2 (PETCO 2 ) was sampled from a nasal cannula and measured using a gas analyzer (model ML206; ADInstruments). Data were attained continuously at 1 kHz per channel via an analog-todigital converter (PowerLab/16SP ML795; ADInstruments) and stored for offline analysis.
Experimental protocol. All experiments were conducted with participants lying supine for safety reasons, recognizing that orthostatic intolerance is a common side effect of ␣ 1-adrenergic blockade. Studies took place in the morning at 0900, and participants had arrived at the laboratory following a light breakfast at ϳ0700 and having abstained from coffee, alcohol, and strenuous exercise for Ն12 h before starting the study. Once the participants acclimatized to the equipment and laboratory environment, 6 min of baseline resting data were recorded. Thereafter, participants breathed a CO 2 gas mixture (5% CO2 with 21% O2 and balanced N2) for ϳ100 s followed by ϳ100 s of voluntary hyperventilation until PETCO 2 had decreased 4 mmHg or more relative to baseline (8) . After the pretreatment CO2 reactivity testing was completed, the active treatment group participants ingested 0.05 mg/kg of the competitive ␣ 1-adrenergic blocker prazosin (with ϳ250 ml water) as previously described (31) , while the placebo group ingested a placebo pill with water. This dose of prazosin has been shown to block ϳ80% of the pressor response to phenylephrine in healthy normotensive participants who were of similar age and body mass index to those in the present study (20, 31) . Participants then repeated the protocol 120 min postingestion to coincide with the peak plasma prazosin concentration (19) . Participants were free to move around within the laboratory environment during the 120-min postingestion period but did not eat or drink. Herein the two groups are referred to as the ␣ 1-adrenergic blockade and placebo group.
Data analysis. From the continuous blood pressure and MCA blood velocity waveforms, we determined beat-to-beat mean arterial pres-sure (MAP) and mean MCA blood velocity (MCA V mean). CO2 reactivity was quantified as the linear relationship between breath-tobreath changes in PET CO 2 and the average beat-to-beat MCAV mean and MAP values within successive breaths after accounting for known physical and physiological latencies. First, to account for the gas sampling delay associated with physical components of the breathing circuit, the entire PET CO 2 trace was left shifted relative to the MCAV mean and MAP time series by 2.6 s. Next, the physiological latency of the CO2 reactivity response was identified as the time interval corresponding to the maximum positive cross-correlation between the PETCO 2 and MCAV mean time series, which was then time shifted to incorporate the delay (Fig. 1 ). Cross-correlation analysis is an accepted approach for estimating the stimulus-response latencies within physiological systems (37) such as the arterial baroreflex (47) and cerebral autoregulation (7, 43) . No delays were introduced to the relation between MAP and MCA V mean.
To estimate the linear relation between PETCO 2 and MCAV mean, we employed linear mixed effects modeling analysis with repeated measures. This approach is a modification of the technique proposed by Dumville et al. (11) , who employed multiple linear regression to derive CO 2 reactivity estimates. In contrast to conventional least squares regression, mixed effects models explicitly account for the fact that repeated PETCO 2 and MCAV mean measurements made within subjects are correlated in nature and therefore violate the case independence assumption required for least squares regression (24) . Furthermore, whereas conventional regression analysis requires x-y data to be reduced to summary measures before secondary analysis using techniques such as ANOVA, mixed effects models analyzes the data in one step without losing valuable information concerning data precision as indicated by the standard error of individual slope estimates (3). Thus parameter estimates are weighted for precision and are more robust. MCA V mean was entered into the model as the primary outcome variable, PETCO 2 as the predictor variable, and MAP as a covariate to control for potential confounding associated with CO2-driven changes in MAP. Random effects terms for subject, PETCO 2 , condition, and intercept were added as the inclusion of these terms maximized the model fit (Akaike information criterion). This analysis was conducted for integrated CO2 reactivity, which represents the relationship between PETCO 2 and MCAV mean across the entire range of PETCO 2 values, and repeated separately for the hypercapnic and hypocapnic regions. The cerebrovascular conductance index (CVC i) was calculated as the MCAV mean divided by the MAP.
Statistical analysis. Linear mixed effects models were implemented as described above. To investigate the overall effects of ␣ 1-adrenergic blockade vs. placebo on CO2 reactivity, we tested for a group ϫ treatment ϫ PETCO 2 interaction as well as all lower order interactions Fig. 1 . Representative raw traces of blood pressure, middle cerebral artery (MCA) blood velocity, and partial pressure of nasal CO2 during CO2 reactivity testing. Progressive hypercapnia and hypocapnia was induced via 5% CO2 inhalation and voluntary hyperventilation. The physiological latency of the CO2 reactivity response was identified as the time interval corresponding to the maximum positive cross-correlation between the partial pressure of end-tidal CO2 (PETCO 2 ) and mean MCA flow velocity (MCAV mean) time series, which was then left shifted to incorporate the delay (9.8 s in this example trace). A strong association between PETCO 2 and MCA V mean was seen in all subjects. Strong associations were also seen between mean arterial pressure (MAP) and MCAV mean, which justify our inclusion of MAP as a covariate in linear mixed effects model analysis (see METHODS). and fixed effects. A significant three-way interaction indicates that the changes in the slope relating PET CO 2 and MCAV mean (i.e., CO2 reactivity) differed between the active treatment and placebo control groups. Statistically significant three-way interactions were followed up with tests for a treatment ϫ PET CO 2 interactions to determine whether CO2 reactivity altered in response to prazosin and placebo. Within-subject (before vs. after treatment) and between-subject (␣1adrenergic blockade vs. placebo) differences in baseline cardiovascular and respiratory parameters were also assessed using linear mixed effects models. Statistically significant two-way interactions were followed up with pair-wise contrasts. Assessment of a priori planned pair-wise comparisons for cardiovascular and respiratory parameters between hypercapnia and hypocapnia vs. baseline were done using Student's paired t-tests. P values were adjusted using the Holm-Bonferroni method to control for the inflation of type 1 error associated with multiple testing (18) . All data were analyzed using customwritten software in LabView 11 (National Instruments, Austin, TX) and SPSS (IBM SPSS statistics version 19, Surrey, UK). For consistency, all data are expressed as means Ϯ SE. Significance was established a priori at P Ͻ 0.05.
RESULTS
Baseline parameters. The effects of ␣ 1 -adrenergic blockade and placebo intervention on baseline parameters are shown in Table 1 . HR was lower following treatment (P Ͻ 0.01) and comparable between groups (P ϭ 0.30 for group effect, P ϭ 0.13 for interaction). There were no interaction or treatment main effects for MAP, indicating that treatment responses to ␣ 1 -adrenergic blockade and placebo were similar. Interaction and main effects were not significant for MCA V mean , PET CO 2 , and CVC i , indicating that neither ␣ 1 -adrenergic blockade nor placebo affected these parameters at baseline. CO 2 reactivity. A representative example of blood pressure, MCAv, and expired CO 2 changes during CO 2 reactivity testing for one subject is shown in Fig. 1 . The cardiovascular and respiratory responses to 5% CO 2 inhalation and voluntary hyperventilation are summarized in Table 2 . Inhalation of 5% CO 2 and subsequent hyperventilation resulted in marked increases and decreases in PET CO 2 , respectively ( Table 2 ). The resultant hypercapnia and hypocapnia consistently altered MCA V mean and CVC i and inconsistently altered MAP or HR ( Table 2 ). The magnitude of hypercapnia was similar between the ␣ 1 -adrenergic blockade and placebo control groups both before and after treatment (main effect for group, P ϭ 0.98; main effect for treatment, P ϭ 0.43; interaction, P ϭ 0.17). Likewise, the magnitude of hypocapnia was similar between the groups and study conditions (main effect for group, P ϭ 0.65; main effect for treatment, P ϭ 0.41; interaction, P ϭ 0.72). Thus the ranges of hypercapnia and hypocapnia achieved before and after ␣ 1 -adrenergic blockade were similar to each other (before vs. after) and similar to placebo.
Linear mixed-effects analysis showed that typically PET CO 2 and MAP were both significant predictors of MCA V mean dynamics, justifying the inclusion of MAP as a covariate. The effects of ␣ 1 -adrenergic blockade or placebo on integrated, hypercapnic, and hypocapnic CO 2 reactivity are summarized in Table 3 and in Fig. 2 , which highlights the magnitude of the treatment effects. Integrated, hypocapnic, and hypercapnic CO 2 reactivity in both the ␣ 1 -adrenergic blockade and placebo groups were reduced following treatment (Fig. 2) . However, three-way interaction (group ϫ treatment ϫ CO 2 ) effects were observed only for the integrated and hypocapnic response, indicating Values are means Ϯ SE for the 6-min baseline recordings. HR, heart rate; MAP, mean arterial pressure; MAP amplitude, mean arterial pressure fluctuation amplitude; MCAV mean, mean middle cerebral artery blood flow velocity; PETCO 2 , partial pressure of end-tidal CO2; CVCi, cardiovascular conductance index. that, after accounting for time-controlled changes (placebo group), ␣ 1 -adrenergic blockade blunted integrated and hypocapnic CO 2 reactivity but not the CO 2 reactivity response to hypercapnia (Fig. 2) . No significant main effects or interactions were found for the integrated, hypercapnic, or hypocapnic CO 2 reactivity delays ( Table 4 ), indicating that ␣ 1 -adrenergic blockade did not alter CO 2 reactivity latency.
DISCUSSION
The main findings of this study were that ␣ 1 -adrenergic blockade: 1) blunted the decrease in CBF evoked by hypocapnia but not the increase in CBF evoked by hypercapnia; and 2) did not alter the CO 2 reactivity latency to hypocapnia or hypercapnia. These results indicate that the sympathetic system contributes to the cerebral vasoconstrictor response to hypocapnia rather than hypercapnia and that the putative influence of ␣ 1 -adrenergic activity on CO 2 reactivity is limited to the magnitude and not the latency of the response. Furthermore, hypercapnic and hypocapnic CO 2 reactivity was blunted in placebo controls, indicative of time-influenced changes in cerebrovascular responsiveness. In the absence of time controls, we would have misleadingly concluded that sympathetic activity modulates CO 2 reactivity to hypercapnia. Therefore, our findings highlight the importance of placebo controls, which have been lacking in most, if not all, previous investigations on the sympathetic regulation of CO 2 reactivity.
Sympathetic regulation of the cerebrovasculature. Although the relevance of the sympathetic system in human CBF control has been the subject of intense debate (44, 46) , our observation that ␣ 1 -adrenergic receptor blockade blunted CO 2 reactivity to hypocapnia suggests that the cerebral vasoconstriction is partly mediated by sympathetic activity. This proposition is physiologically plausible given that the cerebrovasculature purportedly receives rich sympathetic innervation in many animal species (39) , and ␣ 1 -adrenergic receptor stimulation is known to evoke vascular smooth muscle constriction in most vascular beds (16) . Moreover, norepinephrine plasma kinetic measurements made with internal jugular venous sampling have been shown to reflect cerebrovascular sympathetic activity from outside the blood brain barrier (30) , and recent studies have documented impaired cerebral pressure-flow autoregulation following ␣ 1 -adrenergic receptor blockade (15, 31) , which is indicative of active cerebral sympathetic control (5) . Our results support these prior observations and extend them by showing that cerebral sympathetic activity contributes to CBF regulation against dynamic fluctuations in arterial CO 2 .
The notion that hypocapnia might trigger cerebral sympathetic excitation has important implications. Previous studies have shown that muscle (42) and cardiac sympathetic activities (10) increase in response to hypercapnia, not hypocapnia. Therefore, assuming that CO 2 -driven changes in regional sympathetic outflow are all mediated through common afferent pathways, the elevation of cerebral sympathetic activity with hypocapnia implies that sympathetic outflow to the brain might be differentially regulated from the outflow to other vascular beds. Although we did not perform regional sympathetic recordings to verify this possibility, it has been shown that cerebral sympathetic activity in lambs "paradoxically" increases with transient hypertension but not with hypotension (6) . This pattern of activity differs from that associated with regulation of systemic vascular resistance and arterial blood pressure (38) . Thus it is possible that CO 2 may activate superior cervical ganglion neurons in a pattern that does not simply parallel the outflow to other (e.g., muscle) vascular beds. Speculatively, such differential regulation to both baroreflex and chemoreflex stimuli may be teleologically advantageous under situations where CBF stabilization is paramount. For example, cerebral sympathetic excitation in response to hypertension may be an adaptive mechanism that protects the cerebral circulation against excess cerebral perfusion (5). Likewise, cerebral sympathetic excitation during hypocapnia might facilitate vasoconstriction and central pH restoration by reducing CBF and therefore the washout of brain CO 2 . If confirmed, our findings may help explain why sympathetic dysfunction is associated with adverse cerebrovascular outcomes.
While our findings implicate the sympathetic system in CO 2 reactivity to hypocapnia, we recognize that the sympathetic blockade, which has been shown to block ϳ80% of the peripheral vasoconstriction response (20, 32) , only reduced CO 2 reactivity to hypocapnia by ϳ26%. Therefore, hypocapnia-induced vasoconstriction appears to be largely driven independently of ␣ 1 -adrenergic receptor stimulation within the ranges of PET CO 2 we studied. In this context, potential mechanisms for the residual cerebral hypocapnic reactivity warrant brief consideration. The most likely mechanism is that hypocapnia-induced cerebral vasoconstriction is initiated by an increase in local pH. For example, an increase in pH in the vascular smooth muscle decreases the open-state probability of pH sensitive K ϩ channels (e.g., K ATP ) leading to depolarization of the cell membrane, an increase in cytosolic Ca 2ϩ , and reduction in vessel caliber (29) . This notion is based on studies implicating the reciprocal response during hypercapnic vasodilatation (13, 22) . Another possibility is that alterations in vasoactive factors play a role in hypocapnic cerebral vasocon- They found similar levels of endothelin-1, NO metabolites, and adrenomedullin during air breathing and graded hypocapnia down to 24 mmHg PET CO 2 , which is beneath that in the present study. The identification of vasoactive factors responsible for hypocapnic cerebrovascular reactivity extends beyond the scope of our investigation but clearly warrants further research.
In contrast to hypocapnia, ␣ 1 -adrenergic blockade did not blunt the CO 2 reactivity to hypercapnia beyond any timecontrolled changes (placebo group). One interpretation is that sympathetic activity does not play an obligatory role in modulating the vasodilatation response to hypercapnia, which is conceivable given that ␣ 1 -adrenergic stimulation causes vascular smooth muscle constriction rather than dilatation. Our results do not negate the potential for sympathetic activity to effect vasodilatation via ␤-adrenergic receptor stimulation, although previous studies (14, 23, 45) have consistently failed to demonstrate an effect of ␤-adrenergic blockade or stimulation on CBF. Interestingly, the placebo group had blunted integrated, hypercapnic, and hypocapnic CO 2 reactivity indicative of time-influenced changes in cerebrovascular responses to CO 2 . Given our study was designed specifically to examine sympathetic influence on CO 2 reactivity, we cannot explicate the mechanisms underpinning the unexpected changes observed in the placebo group (speculatively, influences could include alterations in intrinsic vasoactive factors such as nitric oxide or endothelin-1). Nevertheless, our findings do highlight the need for physiological studies to incorporate placebo conditions. In the absence of time-controlled trials, we would have overestimated the blunting of CO 2 reactivity to hypocapnia and falsely concluded blunting to hypercapnia following ␣ 1 -adrenergic blockade.
Comparison to previous studies. Several contrasts between this study and previous investigations into the role of the sympathetic system in CO 2 reactivity warrant discussion. One important feature is that all participants in this study were healthy without any preexisting medical history. This may explain why our findings differed from prior investigations conducted in patients afflicted with neurological conditions including recent cerebral ischemia and stroke (28, 41) . Furthermore, this study examined MCA V mean responses to dynamic breath-to-breath changes in PET CO 2 rather than the cerebrovascular response to steady-state changes in PET CO 2 (21, 25) . Steady-state CO 2 reactivity reflects the net effect of all mechanisms engaged by changes in Pa CO 2 and therefore does not take into account the time in which vascular responses occur. Speculatively, the sympathetic input to CO 2 reactivity may be more difficult to detect under steady-state conditions due to functional redundancies between different contributing mechanisms. This methodological difference may partly explain why previous studies employing steady-state approaches have failed to identify a sympathetic influence on CO 2 reactivity (25) . We found that the average CO 2 reactivity delay was ϳ12 s, which is consistent with recent work by Hamner et al. (15) showing that human cerebral sympathetic control operates with a ϳ0.08 Hz (i.e., 12.5 s) dynamic time constant. This delay did not change with ␣ 1 -adrenergic receptor blockade, indicating that the putative influence of ␣ 1 -adrenergic activity on CO 2 reactivity is limited to the magnitude and not the latency of the response.
Methodological considerations and limitations. The results of this study need to be interpreted in cognizance of several methodological considerations. First, blood flow velocity measurements reflect changes in volumetric blood flow only if the diameter of the MCA remain constant. Previous studies employing the same CO 2 reactivity test protocol have confirmed that MCA diameter does remain constant during a range of physiological perturbations including mild to moderate hypocapnia and hypercapnia (40) . Therefore, we consider it reasonable to assume that changes in MCAv measured via transcranial Doppler ultrasound were proportional to changes in CBF. Second, it has previously been suggested that CO 2 -mediated changes in blood pressure may confound CO 2 reactivity estimation (11, 17) . To account for this potential confounding factor, MAP was included as a covariate to explicitly control for its effects when estimating the coefficients relating PET CO 2 to MCA V mean . Our approach is therefore similar to the method proposed by Dumville et al. (11) , who employed a multiple regression model and showed that MAP was a significant predictor of MCA V mean dynamics (in 96% of their participants) and that MAP-adjusted CO 2 reactivity was 20% lower compared with the conventional ratio between relative MCA V mean and PET CO 2 . Nevertheless, it needs to be acknowledged that neither multiple regression nor linear mixed models explicitly account for nonlinearities in the dynamic pressureflow relationship of the cerebral circulation. The development of methods that do account for such nonlinearities may further enhance the estimation of CO 2 reactivity. Third, CO 2 reactivity impairment is associated with an increased risk of stroke (27) and subarachnoid hemorrhage (9) , and predicts poorer prognosis in traumatic brain injury (4) . Further studies are needed to confirm whether cerebral sympathetic dysfunction underpins the deficits in CO 2 reactivity seen in these cerebrovascular conditions. Finally, additional research is needed to verify our speculation that CO 2 -evoked changes in efferent cerebral sympathetic outflow is differentially regulated from efferent sympathetic outflow to the peripheral (e.g., muscle) vasculature. To our knowledge, such concurrent recordings have not been performed in humans during dynamic changes in PET CO 2 . Although it may not be practicable to obtain cerebral sympathetic nerve recordings in conscious human volunteers, a viable alternative is to quantify transcranial plasma norepinephrine spillover from internal jugular venous blood samples taken before and during a hypocapnic challenge (30) .
Conclusion. This study indicates that the sympathetic nervous system contributes to CO 2 reactivity via ␣ 1 -adrenoreceptors as blocking this pathway with prazosin reduced CO 2 reactivity to hypocapnia but not hypercapnia. This observation implicates sympathetic involvement in human CBF regulation specifically against hypocapnia. As different conclusions would have been drawn in the absence of placebo trials, our findings also highlight the importance of time controls, which have been lacking in previous investigations on the sympathetic regulation of CO 2 reactivity.
